研究業績:段孝

免許・資格:

薬学博士、薬剤師、臨床検査技師

 

最近の業績(英文):

 

  1. Ichimura A, Matsumoto S, Suzuki S, Dan T, Yamaki S, Sato Y, Kiyomoto H, Ishii N, Okada K, Matsuo O, Hou FF, Vaughan DE, van Ypersele de Strihou C, Miyata T.A Small Molecule Inhibitor to Plasminogen Activator Inhibitor 1 Inhibits Macrophage Migration.Arterioscler Thromb Vasc Biol.2013; 33(5): 935-942. 
  2. Dan T, van Ypersele de Strihou C, Miyata T. Advanced glycation end products (AGEs) inhibitor. In Oxidative Stress in Applied Basic Research and Clinical Practice Studies on Renal Disorders, edited by Miyata T, Eckardt KU, Nangaku M. 2011 
  3. Ohtomo S, Izuhara Y, Nangaku M, Dan T, Ito S, van Ypersele de Strihou C, Miyata T. Body weight control by a high-carbohydrate/low-fat diet slows the progression of diabetic kidney damage in an obese, hypertensive, type 2 diabetic  rat model. J Obes. 2010.
  4. Izuhara Y, Yamaoka N, Kodama H, Dan T, Takizawa S, Hirayama N, Meguro K, van Ypersele de Strihou C, Miyata T. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates. J Cereb Blood Flow Metab. 2010; 30:904-12. 
  5. Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology (Carlton). 2009;14(6):581-7.
  6. Takizawa S, Dan T, Uesugi T, Nagata E, Takagi S, van Ypersele de Strihou C, Miyata T. A sartan derivative with a very low angiotensin II receptor affinity ameliorates ischemic cerebral damage. J Cereb Blood Flow Metab. 2009;29(10):1665-72
  7. Miyata T. and Dan T. Inhibition of advanced glycation end products (AGEs): An implicit goal in clinical medicine for the treatment of diabetic nephropathy? Diabetes research and clinical practice 2008; 82: Suppl 1:S25-9
  8. Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, Ito S, Nangaku M, van Ypersele de Strihou C, and Miyata T. A novel sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats. Arterio Thromb Vas Biol 2008; 28(10):1767-73
  9. Ohtomo S, Nangaku M, Izuhara Y, Yamada N, Dan T, Mori T, Ito S, van Ypersele C, Miyata T. The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation. Kidney Int 2008, 74(6):768-74

最近の業績(和文):

  

  1. 段孝、市村敦彦、松本幸子、宮田敏男 血管老化の関与-AGEを中心に- 月刊循環器(2012) 2, 51-58
  2. 段孝 多様化する透析医療の最前線 社会をどう変えるのか 創薬プロセスの改革 次世代創薬における大学の新たな役割 臨床透析(2011)27, 50-51
  3. 段孝、宮田敏男.創薬シリーズ トランスレーショナルリサーチ PAI-1阻害薬のトランスレーショナルリサーチ.日本薬理学雑誌(2010)13, 340-343
  4. 段孝 幹細胞を利用したビジネスモデル構築のポイント 「幹細胞の分化誘導と応用」(20092月 エヌ・ティー・エス)pp437-451
  5. 段孝、幹細胞の産業化の現状とわが国の課題 実験医学増刊号(200826-5「再生医療へ進む最先端の幹細胞研究」 818-824

概要 | プライバシーポリシー | サイトマップ
Copyright (C) 2011 Miyata lab. All Rights Reserved.